OSU-T315 induces preferential cytotoxicity in CLL cells. 1E7/mL primary CLL cells from patients; (A) healthy B cells (CD19+) and (B) T cells (CD3+) from leukopaks purified by the CD19+ or CD3+ enrichment kit, respectively, were incubated in complete RPMI with 10% fetal bovine serum followed by increasing dose of OSU-T315 treatment. Cells viability was analyzed by flow cytometry at 24 hours. (C) The response toward OSU-T315 in CLL with cytogenetic abnormalities were analyzed by del(17p13.1) and IGVH status or (D) del(11q22.3) and del(13q14.3). (E) 1E6/mL cells in complete RPMI with 10% fetal bovine serum was incubated and treated with increasing concentration of OSU-T315. Cells viability on treatment in Mec-1 or OSU-CLL cells was examined at 24 hours by Annexin V/PI staining. (F) Three ibrutinib-resistant samples were treated with OSU-T315 for 24 hours in comparison with nonresistant CLL cells; 1 μM ibrutinib was used for treatment for 30 minutes and then washed out; 1 μM CAL-101 was used for treatment for 24 hours.
